Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. (2022)
https://pubmed.ncbi.nlm.nih.gov/35210262/

Frailty in rheumatoid arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank. (2022)
https://pubmed.ncbi.nlm.nih.gov/35292529/

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the IMAPA study. (2022)
https://pubmed.ncbi.nlm.nih.gov/34097014/

Challenges in the diagnosis and assessment of Psoriatic Arthritis. (2022)
https://pubmed.ncbi.nlm.nih.gov/35428713/

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. (2022)
https://pubmed.ncbi.nlm.nih.gov/35640657/

Impact of the COVID-19 pandemic on recruitment to clinical research studies in rheumatology. (2022)
https://pubmed.ncbi.nlm.nih.gov/33938621/

Remotely delivered cognitive behavioural and personalised exercise interventions for fatigue severity and impact in inflammatory rheumatic diseases (LIFT): a multicentre, randomised, controlled, open-label, parallel-group trial (2022)
https://pubmed.ncbi.nlm.nih.gov/36388001/

Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy (2022)
https://pubmed.ncbi.nlm.nih.gov/36596924/

The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/36069174/

Long-term Outcomes Following Severe COVID-19 Infection: A Multicenter Cohort Study of Family Member Outcomes. (2021)
https://pubmed.ncbi.nlm.nih.gov/34192506/

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. (2021)
https://pubmed.ncbi.nlm.nih.gov/34162594/

Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé (2021)
https://pubmed.ncbi.nlm.nih.gov/34844925/

Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. (2021)
https://pubmed.ncbi.nlm.nih.gov/34218429/

The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions (2021)
https://pubmed.ncbi.nlm.nih.gov/34450118/

Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to Go (2021)
https://pubmed.ncbi.nlm.nih.gov/34560915/

Does Age Matter in Psoriatic Arthritis? A Narrative Review (2021)
https://pubmed.ncbi.nlm.nih.gov/34393099/

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study (2021)
https://pubmed.ncbi.nlm.nih.gov/34275488/

TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34229728/

TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors (2021)
https://pubmed.ncbi.nlm.nih.gov/33692019/

The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register (2021)
https://pubmed.ncbi.nlm.nih.gov/33993880/

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials (2021)
https://pubmed.ncbi.nlm.nih.gov/34011674/

Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33928262/

Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study (2021)
https://pubmed.ncbi.nlm.nih.gov/33147607/

Examining the Relationship Between Rheumatoid Arthritis, Multimorbidity, and Adverse Health-Related Outcomes: A Systematic Review (2021)
https://pubmed.ncbi.nlm.nih.gov/33650196/

Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé (2021)
https://pubmed.ncbi.nlm.nih.gov/34844925/

Does Age Matter in Psoriatic Arthritis? A Narrative Review (2021)
https://pubmed.ncbi.nlm.nih.gov/34393099/

Comorbidity burden in axial spondyloarthritis: a cluster analysis. (2020)
https://pubmed.ncbi.nlm.nih.gov/31220322/

Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/31848736/

Treatment strategies in axial spondyloarthritis: what, when and how? (2020)
https://pubmed.ncbi.nlm.nih.gov/33053192/

The IL-23/IL-17A Axis in Spondyloarthritis: Therapeutics Informing Pathogenesis? (2020)
https://pubmed.ncbi.nlm.nih.gov/32412997/

Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/34222775/

Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions (2020)
https://pubmed.ncbi.nlm.nih.gov/33087107/

Classification criteria: time for a rethink? (2020)
https://pubmed.ncbi.nlm.nih.gov/32699035/

T cells and cytokines in inflamed psoriatic skin. Who’s in charge? (2020)
https://pubmed.ncbi.nlm.nih.gov/32686183/

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (2020)
https://pubmed.ncbi.nlm.nih.gov/32641447/

JAK inhibitors and infections risk: focus on herpes zoster (2020)
https://pubmed.ncbi.nlm.nih.gov/32655703/

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? (2019)
https://pubmed.ncbi.nlm.nih.gov/30297330/

Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. (2019)
https://pubmed.ncbi.nlm.nih.gov/30647169/

AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). (2019)
https://pubmed.ncbi.nlm.nih.gov/31143851/

Non-radiographic axial spondyloarthritis (nr-axSpA) – Advances in classification, imaging and therapy. (2019)
https://pubmed.ncbi.nlm.nih.gov/30788779/

Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review. (2019)
https://pubmed.ncbi.nlm.nih.gov/30649569/

Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank (2019)
https://pubmed.ncbi.nlm.nih.gov/31131407/

Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials (2019)
https://pubmed.ncbi.nlm.nih.gov/31070869/

Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions (2019)
https://pubmed.ncbi.nlm.nih.gov/31292564/

Influence of co-morbid fibromyalgia on disease activity measures and response to TNF inhibitors in axial spondyloarthritis: results from a UK national register. (2018)
https://pubmed.ncbi.nlm.nih.gov/30053166/

The co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: Results from a UK national register (BSRBR-AS). (2017)
https://pubmed.ncbi.nlm.nih.gov/28622461/

BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. (2017)
https://pubmed.ncbi.nlm.nih.gov/27558584/

Ankylosing Spondylitis Patients Display Altered Dendritic Cell and T Cell Populations That Implicate Pathogenic Roles for the IL-23 Cytokine Axis and Intestinal Inflammation. (2016)
https://pubmed.ncbi.nlm.nih.gov/26320138/

Modelling health utility values in Ankylosing Spondylitis: Comparisons of direct and indirect methods. (2015)
https://pubmed.ncbi.nlm.nih.gov/26091596/